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Edited by Ned ManteiAbstract RNA and protein analysis revealed the consistent
upregulation of the neural transcription factors ZIC1 and
ZIC4 in desmoid tumors and other ﬁbroproliferative disorders.
The 5 0 ﬂanking region of the ZIC1 promoter was unmethylated
in desmoid tumor ﬁbroblasts, while a hypermethylated ZIC1 pro-
moter was found in human and mouse cell lines not expressing
the gene. In addition, expressing cells showed a H3K4me2 at
the ZIC1 promoter, whereas non-expressing cells showed higher
levels of H3K9me2 in the same region. To our knowledge, this is
the ﬁrst report describing ZIC1 expression in mesenchymal pro-
liferations and a role for DNA methylation in the control of
ZIC1 expression.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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In vertebrates, the ZIC gene family plays an important role
in neural crest and subsequent cerebellar development [1].
Mutations in ZIC family members have demonstrated that
they are essential for proper development of the neural tube,
left-right symmetry, and for muscle and skeletal development.
Although the precise cellular and biochemical activities of
ZIC1 are currently unknown, it has been suggested that
ZIC1 participates in the regulation of cell proliferation in the
dorsal neural tube by inhibition of neural diﬀerentiation [2].
Furthermore, ZIC1 is potentially involved in the oncogenesis
of undiﬀerentiated nervous system tumors [3]. Previously,
our group showed that ZIC1 was consistently upregulated in
desmoid tumors compared to adjacent fascia [4]. This con-
trasted with the fact that ZIC expression was never reported
in adult tissues except neural tissues and tumors. RecentlyAbbreviations: ZIC, zinc ﬁnger protein of cerebellum; H3K4me2,
histone H3 dimethylated at lysine 4; H3K9me2, histone H3
dimethylated at lysine 9; MEF, mouse embryonic ﬁbroblast; TSA,
trichostatin A
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doi:10.1016/j.febslet.2007.09.061the global mapping analysis of stem cells revealed that the
Polycomb proteins (PcGs) regulate the expression of a set of
genes involved in stem cell maintenance and diﬀerentiation,
including ZIC1 [5].
Of the ﬁve ZIC genes identiﬁed in humans and mice, the
gene pairs ZIC1/ZIC4 and ZIC2/ZIC5 both are arrayed
head-to-head in 30 kb genomic regions [6]. The bi-directional
organization of ZIC1 and ZIC4 raises the possibility that the
two genes are regulated by the same enhancer, controlling their
expression in neural and other tissues.
Here we show ZIC1 expression in diﬀerent mesenchymal
proliferations. We will focus on understanding what epigenetic
mechanisms control this expression. Our investigations show
diﬀerences in DNA methylation and in histone modiﬁcations
at the ZIC1 promoter which correlate with the expression lev-
els of the gene. Moreover, we will show the co-expression of
ZIC1 and ZIC4 while ZIC2, ZIC3, and ZIC5 are not ex-
pressed in the diﬀerent ﬁbroproliferative states.2. Materials and methods
2.1. Cell lines
Surgical resection specimens were obtained from patients undergo-
ing surgery for a desmoid tumor at our University Hospital. Primary
cell cultures were obtained by collagenase treatment and subsequently
grown in D-MEM/F-12 supplied with 10% FCS. All tumor samples
were diagnosed as desmoids, based on their pathology and mutational
status. Biopsy material was snap frozen and stored at 70 C. Forma-
lin-ﬁxed, paraﬃn-embedded samples of skin tissue, desmoid tumors,
Dupuytren’s disease and hypertrophic scars were obtained from the
department of pathology of the University Hospital. The cell lines
NIH 3T3, mouse embryonic ﬁbroblast (MEF), SW480, CCL222,
HCT116, Caco2, HTB185 and HTB186 were obtained from the Amer-
ican Type Tissue Culture Collection. For 5-aza-2 0-deoxycytidine (5-
aza-dC) treatments, cells were grown at low density in T-75 dishes
and treated with diﬀerent doses of 5-aza-dC (Sigma, Belgium) for a
total duration of 3 days.2.2. Real-time quantitative RT-PCR (TaqMan)
The PCR protocol was carried out as recommended by Applied Bio-
systems. Standard curves for targets and the housekeeping control
gene PBGD (Porphobilinogen Deaminase) were drawn based on the
Ct (threshold cycle) values, and the relative concentrations of the stan-
dards and the relative concentrations for samples were calculated from
the detected Ct values and the equation of the curves. Values obtained
were divided by the values of PBGD to normalize for diﬀerences in re-
verse transcription. The primers used in these investigations are given
in the supplementary material.blished by Elsevier B.V. All rights reserved.
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Twenty lg of total RNA was denatured in a MOPS/formaldehyde/
formamide buﬀer, run on a 1% agarose gel and transferred on Hy-
bond-N nitrocellulose membranes (Amersham Biosciences). Speciﬁc
probes for ZIC1 and PBGD were generated and 32P-labelled (se-
quences available upon request). After prehybridization, hybridization
was carried out overnight at 68 C in ExpressHyb hybridization solu-
tion (Clontech, BD Biosciences). Membranes were washed for 1 h at
42 C with a 2 · SSC/0.1% SDS solution and for 1 h at 62 C with a
0.1 · SSC/0.1% SDS solution. After autoradiography, blots were
stripped and hybridized with a housekeeping probe (PBGD).
2.4. Western blot
Protein samples were run on a 10% BisTris gel (Invitrogen Life
Technologies) and electroblotted on Hybond-C nitrocellulose mem-
branes (Amersham Biosciences). The following antibodies were used:
polyclonal rabbit anti-ZIC1 (1/1000) (Abcam, UK), mouse monoclo-
nal anti-GAPDH (loading control, 1/10000) (Abcam, UK).
2.5. Immunohistochemistry
Sections from patient samples (5 lm) were dewaxed and then
quenched in a 0.3% hydrogen peroxide/methanol solution (30 min).
Monoclonal anti-ZIC1 Ab (1:100) was diluted in PBS-BSA/10% goat
serum/0.1% Triton X-100 and applied for 3 h at room temperature.
Immunohistochemical staining was performed using the EnVision+
System-HRP Mouse Kit (DakoCytomation, Belgium). Nuclei were
stained with hematoxylin. The monoclonal anti-ZIC1 antibody was a
kind gift from Prof. Mikoshiba and Prof. Aruga [3].
2.6. Sodium bisulﬁte genomic sequencing
One microgram of genomic DNA was modiﬁed with sodium bisul-
ﬁte using the EZ DNA Methylation Kit (Zymo Research USA).
PCR primers speciﬁc to the bisulﬁte-modiﬁed sequences of the ZIC1
CpG islands were generated (sequences available upon request).
PCR amplicons were puriﬁed (Millipore) and sequenced on an ABI
automated DNA sequencer. The methylation status of individual
CpG sites was determined by taking the ratio of the amplitude of
the methylated cytosine (appears as C) with that of the unmethylated
cytosine (appears as T) described by Lewin et al. [7]. Normalization of
peak heights of diﬀerent bases was done before any ratio was deter-
mined. The normalizing factor for each base was computed by taking
the average peak height of the same base across the whole sequence
divided by the peak heights of all peaks.Fig. 1. ZIC1 expression in desmoid tumors compared with adjacent fascia.
cultures and medulloblastoma cells HTB-186 used as control. The values give
nine desmoid biopsies. (C) Western blot analysis of the ZIC1 protein in the s
shown in A.2.7. Chromatin immunoprecipitation assay
The chromatin immunoprecipitations (CHIP) were performed as de-
scribed previously with slight modiﬁcations [8]. Antibodies used were
as follows: anti-di-methylated histone H3K4 (Upstate Biotechnology),
anti-tri-methylated H3K27 (Upstate Biotechnology) anti-di-methyl-
ated H3K9 (Upstate Biotechnology). The relative occupancy of the
immunoprecipitated factor at a locus was estimated using the follow-
ing equation: 2(Ct mock  Ct speciﬁc), where ‘‘Ct mock’’ and ‘‘Ct
speciﬁc’’ correspond to the mean threshold cycles of a qPCR reaction
done in duplicate on DNA samples from mock and speciﬁc immuno-
precipitations.3. Results
3.1. ZIC1 is highly expressed in desmoid tumors and other
ﬁbroproliferative states
Compared to the high expressing medulloblastoma cell line
HTB186, real-time RT-PCR showed even higher ZIC1 expres-
sion in four primary cultures and nine biopsies, whereas none
of the corresponding fascia samples expressed ZIC1 (Fig. 1A
and B). ZIC1 expression was conﬁrmed via Western blot on
the same samples. A band of 54 kDa corresponding to ZIC1
was seen in all desmoid samples whereas fascia samples
showed no ZIC1 protein (Fig. 1C). To validate the quantitative
RT-PCR results, Northern blot analysis was performed on
four desmoid and fascia cultures. A band at 3.1 kb for ZIC1
was detected in all desmoid samples (Fig. 1D), but not in the
fascia samples. The colon carcinoma cell lines SW480,
CCL220, Caco and HCT116 as well as the mouse NIH 3T3 cell
line were ZIC1 negative, while the mouse embryonic ﬁbro-
blasts, MEF cells, expressed small amounts of ZIC1 (results
not shown). Immunohistochemical staining was performed
on ﬁve desmoids, ﬁve palmar ﬁbromatoses (Dupuytren’s dis-
ease) and ﬁve non-tumoral hypertrophic scars (keloids). In
all samples, the majority of cells showed nuclear staining,
although some cytoplasmic ZIC1 expression was present
(Fig. 2).(A) RT-PCR analysis of ZIC1 expression in four desmoid, four fascia
n in ordinate are relative to HTB-186 set at 100. (B) ZIC1 RT-PCR in
amples shown in A. (D) Northern blot analysis of ZIC1 in the samples
Fig. 2. Immunohistochemical ZIC1 localization in desmoid tumors and other ﬁbromatoses. Strong nuclear staining with the monoclonal anti-ZIC1
antibody is present in most tumoral cells and activated ﬁbroblasts. No ZIC1 expression is seen in resting skin ﬁbroblasts. Some unspeciﬁc staining,
also present in the negative controls, is seen in the epithelial compartment through cross reaction of the secondary antibody.
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The expression of human ZIC2, ZIC3, ZIC4 and ZIC5 was
examined in four primary cultures and nine desmoid biopsies.
ZIC2, ZIC3 and ZIC5 were not expressed in desmoid nor fas-
cia samples. Only ZIC1 and ZIC4 were co-expressed in all
desmoids samples (see supplementary material).
3.3. Proﬁles of DNA methylation and histone modiﬁcations at
the ZIC1 promoter
Analysis of the 5 0-ﬂanking region of the ZIC1 gene with the
MethyPrimer software (Applied Biosystem) showed the pres-
ence of two CpG islands, one expanding from transcription
start site to 850 (CpG1) and the other one from 1628 to
2736 (CpG2). A 280-bps amplicon of CpG1 covering 22
CpG sites which is identical in both human and mouse was
tested for its methylation status (Fig. 3). We checked the
DNA methylation status of desmoid and fascia biopsies and
also NIH 3T3 cells. Desmoid cells were hypomethylated com-
pared to the high methylation of adjacent fascia (Fig. 3). NIH
3T3 and colon cancer cell lines (SW480, CCL222, Caco2 and
HCT116) showed fully methylated CpGs whereas the medullo-
blastoma cell lines (HTB185 and HTB186) showed complete to
partially unmethylated CpGs of the same region. The methyl-
ation of the ZIC1 promoter correlated with the degree of
expression of ZIC1 in all those cell lines.
3.4. Eﬀect of 5-aza-dC treatment on ZIC1 expression in fascia
and NIH 3T3 cells
Fascia and NIH 3T3 cells were treated with diﬀerent concen-
trations of 5-aza-2 0-deoxycytidine (5-aza-dC) for 3 days and/or
for 12–24 h with 100 nM histone deacetylase inhibitor tricho-
statin A (TSA). Upon 5-aza-dC treatment, the transcription
of ZIC1 was reactivated in fascia (up to7-fold) and in NIH3T3 cells (up to 26-fold) (see supplementary material). TSA
showed a synergistic eﬀect when combined with 5-aza-dC,
but alone did not result in gene induction. No change in
Zic1 expression was observed in MEF (Zic1 expressing cells)
after 5-aza-dC and/or TSA treatment (data not shown). NIH
3T3 cells treated with diﬀerent concentrations of 5-aza-dC
showed decreased methylation of the Zic1 promoter in a
dose-dependent way (see supplementary material).
3.5. Histone methylation
We also determined the chromatin modiﬁcations at the
ZIC1 promoter by measuring speciﬁc histone methylation
within the CpG1 island. The ZIC1 promoter was associated
with the active chromatin marker histone H3 dimethylated at
lysine 4 (H3K4me2) in desmoids whereas the histone H3 dime-
thylated at lysine 9 (H3K9me2) was present at the promoter of
the fascia cells (Fig. 4A). Similarly, Zic1-positive cells (MEF),
showed a higher level of H3K4me2 whereas H3K9me2 was
more abundant in the Zic1-negative cell line, NIH 3T3
(Fig. 4B). Recently methylation of histone H3 at lysine 27
has been linked to ZIC1silencing in stem cells [9]. We did
not observe any H3K27me2 in non-expressing adult cells.4. Discussion
Despite the crucial role described for ZIC1 in development,
information about this gene in adult tissues or its implication
in tumorigenesis is limited. While no expression has ever been
described in adult tissues outside the brain or brain tumors [3],
here we conﬁrm by immunohistochemical methods the high
expression of ZIC1 in desmoid tumors and ﬁbroproliferative
diseases as well as in proliferating skin ﬁbroblasts. RT-PCR
ig. 3. Methylation proﬁle of theZIC1 promoter in diﬀerent cell lines. Schematic representation of the regulatory region of the human ZIC1 gene
howing methylation rates of the 22 CpG dinucleotides in fascia, desmoid colon cancer cell lines, SW480, CCL222, HCT116 and medulloblastoma
ell lines HTB185, HTB186. The gray shading represents the diﬀerent methylation rates as indicated on the scale bar. Human ZIC1 accession
umber: NC_000003.
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s
c
nFig. 4. Proﬁles of histone modiﬁcations at the ZIC1 promoter CpG island. A higher level of H3K4me2 in desmoids is found compared with adjacent
fascia. Fascia shows a higher level of H3K9me2 in the same region. The results are expressed as ratios of the real-time PCR signals obtained for IP
with speciﬁc antibodies to those obtained for mock IP with IgG.showed the high and selective co-expression of ZIC1 and ZIC4
in the desmoid tumor cells and their absence in control fascia
ﬁbroblasts.
We could show a good correlation between the methylation
status of the promoter region of the ZIC1 gene and its expres-
sion at the RNA and protein level. Hypomethylation wasfound in desmoids whereas the adjacent fascia tissue showed
hypermethylation. The ZIC1 promoter was also densely meth-
ylated in the colon cancer cell lines, SW480, CCL222, Caco2
and HCT116, which do not express either ZIC1 or ZIC4.
5-aza-dC treatment showed a quantitative correlation between
ZIC1 expression and demethylation of the ZIC1 promoter.
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treatment in NIH 3T3 cells (data not shown).
The chromatin immunoprecipitation approach showed a
high level of H3K4me2 at the ZIC1 promoter in desmoids,
whereas fascia cells showed more H3K9me2 in the same re-
gion. H3K9 dimethylation seems to be a robust epigenetic
mark of ZIC1 gene suppression because the other non-express-
ing cell line, SW480, also showed enrichment of H3K9me2.
The zic1 promoter was also selectively enriched in dimethyl-
ated histone H3 at lysine 4 in the zic1 expressing MEF cells
but was depleted in H3K4 and enriched in H3K9 in the NIH
3T3 cells where it is silent. Thus, the regulation of ZIC1 gene
expression is also aﬀected by histone modiﬁcations in regula-
tory territories of the ZIC1 promoter. While TSA treatment
in itself could not induce the expression of zic1, the fact that
the eﬀect was synergistic with 5-aza treatment suggests that
the DNA methylation is the primary control of the expression.
A recent study provided evidence for transcriptional regula-
tion of ZIC1 in human embryonic stem cells by polycombs.
They have suggested that ZIC1, as a target gene of EZH2,
might be permanently silenced due to secondary epigenetic
modiﬁcations such as DNA methylation. Interestingly, bisul-
ﬁte sequencing of mouse embryonic stem cells (zic1 negative
cells) did not show any methylation at the promoter region
(unpublished data). However, recent study identiﬁed a speciﬁc
modiﬁcation pattern for ZIC1, termed ‘‘bivalent domains’’,
consisting of large regions of H3K27me3 harboring smaller re-
gions of H3K4me3 [9]. This is altered to H3K4me3 only in dif-
ferentiated neural precursors, correlating with greater than a
600 times increase in ZIC1 gene expression [10].
In summary, we have shown that ZIC1 is highly expressed in
desmoid tumors and other ﬁbroproliferative states through
epigenetic mechanism. The epigenetic determinants associated
with the control of ZIC1 expression occur in the 5 0 regulatory
region of the ZIC1 gene and involve cytosine methylation and
methylation of the associated H3 histone. In view of the cellu-
lar heterogeneity of the tumor biopsies and cultures, the results
represent a mean of all the cells examined and may hide indi-
vidual diﬀerences between cells in diﬀerent phases of growth or
malignant transformation.
This is the ﬁrst report describing ZIC1 expression in mesen-
chymal proliferations and a role for DNA methylation in the
control of ZIC1 expression. Although, the biological signiﬁ-
cance of ZIC1 overexpression in desmoid is still not clear,
our ﬁndings suggest that ZIC1 could be important for the
development and proliferative behavior of this neoplasm.Acknowledgements: We thank Prof. Mikoshiba and Prof. Aruga for
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genetics.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febslet.2007.
09.061.
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